Lung Cancer

The study evaluated the efficacy and safety of Dato-DXd compared to docetaxel in adult patients with locally advanced or metastatic NSCLC with and without actionable genomic alterations who require systemic therapy following prior treatment.

First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.

According to a recent study in JAMA Network Open, robotic-assisted lung surgeries take a bit longer but seem to be just as safe as video-assisted surgeries.

Cancer patients not only experience the physical and mental toll of treatments like chemotherapy but also face "financial toxicity" due to high out-of-pocket costs, which can challenge their ability to work.

A group of researchers recently aimed to investigate the prognosis of patients with NSCLC that lacked a spouse, family members, or friends to support them during cancer treatment.

The term "time toxicity" has been coined for the large amounts of time taken up healthcare that may interfere with other priorities.

Enhertu demonstrated antitumor activity against HER2-overexpressing metastatic NSCLC in the trial.

In the U.S., nearly 200,000 new cases of lung cancer were reported in 2020, with over 100,000 deaths. While the number of lung cancer deaths has generally decreased over the past 20 years, lung cancer remains the leading cause of cancer deaths in the US and is the third most common type of cancer.

Initial treatments for lung adenocarcinomas may be effective at first, but sometimes these tumors can respond by turning into small cell lung cancer (SCLC), a more aggressive and difficult-to-treat disease.

It is well-known that smoking is linked to a higher risk of cancer, and those who smoke can lower their risk by quitting. However, it remains unclear exactly how many years of continued smoking cessation are needed to see a substantial risk reduction.

Gilead's share price fell 10% today after it announced that Trodelvy, an antibody-drug conjugate, failed to meet its overall survival end point in a trial testing it as treatment for metatstatic non-small cell lung cancer.

Post-operative mortality rates decreased 30 and 90 days after surgery.

While tissue biopsy is currently recommended as the gold standard for determining mutations in non-small cell lung cancer, its success is not guaranteed, prompting the consideration of the liquid biopsy method as a viable alternative.

Trial results revealed that tumors shrank in 40% of patients who received the 10-mg dose of tarlatamab and in about 32% of those who received the 100-mg dose.

Study suggests that low-fat meals may affect blood concentration levels, and high blood concentration has been correlated with a better response to the drug.

Findings from the ADAURA trial argue for starting treatment with the AstraZeneca drug early, says Yale’s Roy Herbst, M.D., Ph.D., the principal investigator.

In a clinical trial, researchers concluded that direct oral anticoagulants were non-inferior to low-molecular-weight heparin.

Researchers in Spain explore strategies for making tumor microenvironment less “tumor permissive.” Their experiments were in mice models of the lung cancer, so the findings are from early-stage research and far from the final word.

The findings provide evidence that the MYC family of oncogenes is a driver of resistance.

Study of patients treated with Tecentriq (atezolizumab) shows the risk of hyperprogression is .7% when the PD-L1 is used as a first-line therapy and 8.8% when it was used in later lines of therapy.

Researchers find an association between depression and biomarkers for inflammation, which may mean a poor prognosis.